Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer

PURPOSE: Assess efficacy and toxicity of gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, added to, and in maintenance after, concurrent chemoradiotherapy (CCRT) in locally advanced head and neck cancer (LA-HNC) and correlate outcomes with EGFR gene copy number alterations. PATIENTS...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Cohen, Ezra E.W., Haraf, Daniel J., Kunnavakkam, Rangesh, Stenson, Kerstin M., Blair, Elizabeth A., Brockstein, Bruce, Lester, Eric P., Salama, Joseph K., Dekker, Allison, Williams, Rosalyn, Witt, Mary Ellyn, Grushko, Tatyana A., Dignam, James J., Lingen, Mark W., Olopade, Olufunmilayo I., Vokes, Everett E.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2010
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2903330/
https://ncbi.nlm.nih.gov/pubmed/20498391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.27.0397
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires